Chromium-Containing Traditional Chinese Medicine, Tianmai Xiaoke Tablet, for Newly Diagnosed Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review of Randomized Clinical Trials

Table 1

Basic characteristics of the included studies.

First author, year	Sample size; (T/C)	Population characteristics	Treatment	Control	Duration of treatment	Follow-up	Outcome assessment
Gao, 2016 [10]	100 (50/50)	T: mean age (51.32 years); M/F (28/22 cases); C: mean age (51.16 years); M/F (24/26 cases)	TMXKT 0.24 g/time, Bid + control	Metformin; 0.5 g/time, Tid	3 months	None	FPG; 2HPG; HbA1c
Huang, 2016 [11]	86 (42/44)	T: mean age (NA); M/F (18/24 cases); C: mean age (NA); M/F (21/23 cases)	TMXKT 0.24 g/time, Bid + control	Metformin; 0.5 g/time, Tid	12 weeks	None	FPG; 2HPG; HbA1c; BMI
Liang, 2014 [12]	134 (69/65)	T: mean age (52 years); M/F (32/37 cases); C: mean age (56 years); M/F (29/36 cases)	TMXKT 0.24 g/time, Bid + control	Metformin; 0.5 g/time, Tid	12 weeks	None	FPG; 2HPG; HbA1c
Shao, 2017 [13]	80 (40/40)	T: mean age (NA); M/F (NA); C: mean age (NA); M/F (NA)	TMXKT 0.24 g/time, Bid + control	Metformin; 0.5 g/time, Bid	12 weeks	None	FPG; 2HPG; HbA1c
Yuan, 2011 [14]	120 (60/60)	T: mean age (NA); M/F (36/24 cases); C: mean age (NA); M/F (34/26 cases)	TMXKT 0.24 g/time, Bid + Metformin; 0.25 g/time, Tid	Metformin; 0.5 g/time, Tid	3 months	None	FPG; 2HPG; HbA1c; BMI
Shi, 2015 [15]	105 (53/52)	T: mean age (NA); M/F (36/24 cases); C: mean age (NA); M/F (34/26 cases)	TMXKT 0.24 g/time, Bid; + control	Aspart insulin 30; 12–16 U/time,; Bid	16 weeks	None	FPG; 2HPG; HbA1c; BMI
Tan, 2015 [16]	92 (46/46)	T: mean age (50.18 years); M/F (33/13 cases); C: mean age (49.82 years); M/F (34/12 cases)	TMXKT 0.24 g/time, Bid; + control	Pioglitazone,; 15 mg/time Bid	8 weeks	None	FPG

BMI, body mass index; FPG, fasting blood glucose; HbA1c, glycosylated hemoglobin A1c; 2HPG, 2-h postprandial blood glucose; TMXKT, Tianmai Xiaoke tablet.